Aurobindo Pharma Limited (BOM:524804)
India · Delayed Price · Currency is INR 1,432.40
+1.50 (0.10%)
At close: Jun 1, 2026
Aurobindo Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 35,048 | 34,859 | 31,730 | 19,275 | 26,482 |
Depreciation & Amortization | 17,782 | 15,212 | 14,394 | 11,962 | 10,833 |
Other Amortization | - | 699.6 | 525.2 | 413.1 | 432.4 |
Loss (Gain) From Sale of Assets | 243 | 89.4 | -234.9 | -132.3 | 1,558 |
Asset Writedown & Restructuring Costs | 317.6 | 696.4 | 623.7 | 309.9 | -396.3 |
Loss (Gain) From Sale of Investments | -14.2 | -367 | -1 | - | -264.3 |
Loss (Gain) on Equity Investments | -15.2 | 316.9 | 171.5 | 116.7 | 312.5 |
Provision & Write-off of Bad Debts | 132.6 | 188 | 232.8 | 524.5 | -61.1 |
Other Operating Activities | 131.2 | -3.5 | -6,345 | 2,348 | -4,309 |
Change in Accounts Receivable | -11,707 | -8,621 | -2,642 | -4,321 | -4,108 |
Change in Inventory | -14,998 | -7,355 | -13,037 | -9,267 | 14,975 |
Change in Accounts Payable | 12,816 | -3,109 | 5,828 | 7,077 | 1,107 |
Change in Other Net Operating Assets | 15,529 | 6,640 | -6,900 | -4,438 | 3,605 |
Operating Cash Flow | 55,264 | 39,246 | 24,345 | 23,868 | 50,165 |
Operating Cash Flow Growth | 40.81% | 61.21% | 2.00% | -52.42% | 50.69% |
Capital Expenditures | -26,858 | -19,679 | -27,803 | -24,038 | -20,529 |
Sale of Property, Plant & Equipment | 462.5 | 28.4 | 602.8 | 110.9 | 3,809 |
Cash Acquisitions | -3,032 | -113.9 | - | -1,970 | -5,814 |
Divestitures | - | - | - | - | 43.2 |
Sale (Purchase) of Intangibles | -4,189 | -5,517 | -7,812 | -3,166 | -6,517 |
Investment in Securities | -7,819 | 881.6 | 1,535 | 4,428 | -3,361 |
Other Investing Activities | 6,849 | 5,641 | -9,082 | -15,142 | 252.6 |
Investing Cash Flow | -34,586 | -18,758 | -42,560 | -39,778 | -32,116 |
Short-Term Debt Issued | 3,592 | 20,611 | - | 20,697 | - |
Long-Term Debt Issued | 3,607 | 6,614 | 15,632 | 3,936 | 827.3 |
Total Debt Issued | 7,199 | 27,226 | 15,632 | 24,633 | 827.3 |
Short-Term Debt Repaid | - | - | -847.6 | - | -26,367 |
Long-Term Debt Repaid | -14,125 | -12,287 | -1,638 | -981.2 | -1,331 |
Total Debt Repaid | -14,125 | -12,287 | -2,485 | -981.2 | -27,698 |
Net Debt Issued (Repaid) | -6,927 | 14,939 | 13,147 | 23,651 | -26,871 |
Repurchase of Common Stock | - | -9,302 | - | - | - |
Common Dividends Paid | -2,324 | -10.4 | -2,636 | -4,395 | -2,637 |
Other Financing Activities | -3,441 | -4,428 | -2,507 | -1,112 | -185 |
Financing Cash Flow | -12,692 | 1,198 | 8,004 | 18,144 | -29,693 |
Foreign Exchange Rate Adjustments | 8,288 | 91 | 141.7 | -0.6 | 2 |
Miscellaneous Cash Flow Adjustments | 1.8 | 6.6 | - | 64.1 | -32.5 |
Net Cash Flow | 16,276 | 21,784 | -10,068 | 2,298 | -11,674 |
Free Cash Flow | 28,406 | 19,568 | -3,458 | -170.5 | 29,636 |
Free Cash Flow Growth | 45.17% | - | - | - | 56.71% |
Free Cash Flow Margin | 8.44% | 6.17% | -1.19% | -0.07% | 12.63% |
Free Cash Flow Per Share | 48.91 | 33.57 | -5.90 | -0.29 | 50.58 |
Cash Interest Paid | 3,441 | 4,203 | 2,507 | 1,112 | 185 |
Cash Income Tax Paid | 18,320 | 17,314 | 17,666 | 7,172 | 12,582 |
Levered Free Cash Flow | 13,185 | 11,519 | -12,590 | -4,803 | 12,129 |
Unlevered Free Cash Flow | 15,585 | 14,271 | -10,914 | -3,997 | 12,359 |
Change in Working Capital | 1,639 | -12,445 | -16,751 | -10,950 | 15,578 |